COMPANY PROFILE

Cytocares

Explore full profile

McBride congratulates Hue and the three biological antibodies CC312 for obtaining FDA approval for the clinical trial

ChinaFounded 2015Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Cytocares

CytoCares is a pioneering biotechnology company specializing in the development of advanced immuno-oncology therapies. The company focuses on creating proprietary therapeutic platforms such as TriTE™, CCNK™, and TM, which are designed to stimulate or modulate immune cells to fight against various forms of cancer, including both hematologic malignancies and solid tumors. CytoCares serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, operating primarily in the biopharmaceutical market. The business model revolves around the research, development, and commercialization of its unique therapeutic platforms. Revenue is generated through partnerships, licensing agreements, and the sale of its proprietary therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: China
Open positions: None listed
Dealroom signal: 21.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Oct 2025	$9.3M	$101M	Shanghai Tellgen Life Science	↗
SERIES A✓Equity / VC	May 2023	$14M	$55M	Shenzhen Capital Group · Jinyu Maowu Investment · Prosperico Ventures · BostonGene	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Cytocares website traffic

Latest recorded traffic for Cytocares is 400 monthly website visits, down 36.5% over the last three months.

Latest monthly visits400 3-month web change-36.5%

Monthly website visitsMay 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PTPineTree TherapeuticsDevelops targeted protein degraders for drug-resistant cancers and other diseases	Cambridge, United States	Operational	41	$88M	$188M
YBYatiri BioYatiri Bio – Beyond Genes	San Diego, United States	Operational
SESeekGeneProvider of genetic data analysis solutions focused on the development and clinical transformation	Guangzhou, China	Operational
MIMelliCell, Inc.Develops therapeutics for diabetes and obesity using proprietary technologies that model weight gain in human fat cells in vitro	Newton, United States	Operational
KFKFBIOAI-Powered world-leading digital pathology slide Scanner Manufacturer	Ningbo, China	Operational
TBThunder BiotechBiotech company that provides a full platform for a complete cancer cure solution	Provo, United States	Operational
ETEvox TherapeuticsExosome-based gene editing therapies for neurological diseases	Oxford, United Kingdom	Operational
PBPBD BiotechRapid bacteriophage-based diagnostics for mycobacterial diseases	Birmingham, United Kingdom	Operational